| name | Dysport |
| active ingredient | abobotulinumtoxinA |
| classification | Neuromuscular blocking agent, Botulinum toxin type A |
| pharmacokinetics | Following intramuscular injection, abobotulinumtoxinA is rapidly absorbed and transported to the neuromuscular junction, inhibiting acetylcholine release. Effects typically develop within a few days and the duration of action varies based on injection site and dose. Elimination is not easily measured due to the toxin's sustained neuromuscular blocking effect. |
| suggested dosage | Dosage varies by patient and condition. Consult with a physician for appropriate dosage and treatment plan. |
| indications | | 1 | Cosmetic use (e.g., facial wrinkles) | | 2 | Spasticity associated with various neurological conditions (e.g., cerebral palsy, multiple sclerosis) | | 3 | Blepharospasm | | 4 | Strabismus (eye misalignment) | | 5 | Migraine (prevention) | | 6 | Hyperhidrosis (excessive sweating) |
|
| safety pregnancy | Limited data; use only if potential benefit outweighs potential risk. Consult a physician. |
| safety breastfeeding | Limited data; use only if potential benefit outweighs potential risk. Consult a physician. |
| side effects | | 1 | Injection site reactions (pain, redness, swelling) | | 2 | Headache | | 3 | Fatigue | | 4 | Dry mouth | | 5 | Muscle weakness | | 6 | Dysphagia (difficulty swallowing) | | 7 | Vision changes | | 8 | Hoarseness | | 9 | Flushing | | 10 | Bruising | | 11 | Allergic reactions (rare) | | 12 | Ptosis (drooping eyelid) | | 13 | Diplopia (double vision) | | 14 | Nausea |
|
| alternatives | | 1 | | | 2 | | name | Botox | | active ingredient | onabotulinumtoxinA |
| | 3 | | name | Vistabel | | active ingredient | rimabotulinumtoxinB |
|
|
| contraindications | | 1 | Known hypersensitivity to botulinum toxin A or components | | 2 | Active infection at injection site | | 3 | Severe neuromuscular disorders |
|
| interactions | Limited interaction data; consult a physician or pharmacist. |
| warnings precautions | | 1 | Use with caution in individuals with neuromuscular disorders. | | 2 | Careful consideration of benefit-risk ratio in pregnancy and breastfeeding. | | 3 | Use only as directed by a qualified medical professional. | | 4 | Proper injection technique crucial to avoid complications. | | 5 | Monitor for adverse events post-injection. |
|
| additional information | | 1 | Individual responses to Dysport vary. | | 2 | Effectiveness can decrease over time, requiring repeat treatments. | | 3 | This information is for general knowledge only and is not a substitute for professional medical advice. | | 4 | Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition or treatment. |
|
| patient details | | age | 25 | | weight | 70 | | gender | male | | notes | Patient-specific data is for illustrative purposes only and should not be used for medication decisions. |
|
| source | Example Database, updated Oct 26, 2023 |
